Effect of reoxygenation on the hypoxia-induced up-regulation of serine protease inhibitor PAI-1 in head and neck cancer cells

Oncology

Volumn 71, Issue 3-4, 2007, Pages 282-291

  Sprague, Lisa D ^a,b   Mengele, Karin ^b   Schilling, Daniela ^b   Geurts Moespot, Anneke ^d   Sweep, Fred C G J ^d   Stadler, Peter ^c   Schmitt, Manfred ^b   Molls, Michael ^b  

^a FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Praxis Mühleninsel ^*  (Germany)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Head and neck cancer; Hypoxia; Plasminogen activator inhibitor 1; Reoxygenation; Urokinase type plasminogen activator

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE INHIBITOR;

ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL ADHESION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FIBROBLAST; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HYPOXIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REOXYGENATION; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; UPREGULATION;

CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OXYGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; UP-REGULATION; URINARY PLASMINOGEN ACTIVATOR;

EID: 34548059487     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000106789     Document Type: Article

References (42)

1. Yuan J, Narayanan L, Rockwell S, Glazer PM: Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer Res 2000;60:4372-4376.
2. Le QT, Denko NC, Giaccia AJ: Hypoxic gene expression and metastasis. Cancer Metastasis Rev 2004;23:293-310.
3. Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D: Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002;7:492-508.
4. Dietz A, Vanselow B, Rudat V, Conradt C, Weidauer H, Kallinowski F, Dollner, R: Prognostic impact of reoxygenation in advanced cancer of the head and neck during the initial course of chemoradiation or radiotherapy alone. Head Neck 2003;25:50-58.
5. Hill RP, Fyles W, Milosevic M, Pintilie M, Tsang RW: Is there a relationship between repopulation and hypoxia/reoxygenation? Results from human carcinoma of the cervix. Int J Radiat Biol 2003;79:487-494.
6. Fitzpatrick TE, Graham CH: Stimulation of plasminogen activator inhibitor type-1 expression in immortalized human trophoblast cells cultured under low levels of oxygen. Exp Cell Res 1998;245:155-162.
7. Andreasen PA, Kjoller L, Christensen L, Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997;72:1-22.
8. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Höfler H, Jänicke F, Graeff H: Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 1997;78:285-296.
9. Duffy MJ: The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004;10:39-49.
10. Uchiyama T, Kurabayashi M, Ohyama Y. Utsugi T, Akuzawa N, Sato M, Tomono S, Kawazu S, Nagai R: Hypoxia induces transcription of the plasminogen activator inhibitor type-1 gene through genistein-sensitive tyrosine kinase pathways in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2000;20:1155-1161.
11. Wang Z, Kurpakus-Wheater, M: Decreased plasminogen activator inhibitor type-1 secretion in hypoxic corneal epithelial cells is associated with increased urokinase plasminogen activator activity. Int J Biochem Cell Biol 2003;35:339-348.
12. Kroon ME, Koolwijk P, van der Vecht B, van Hinsbergh VW: Urokinase receptor expression on human microvascular endothelial cells is increased by hypoxia: implications for capillary-like tube formation in a fibrin matrix. Blood 2000;96:2775-2783.
13. Graham CH, Forsdike J, Fitzgerald CJ, Macdonald-Goodfellow S: Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int J Cancer 1999;80:617-623.
14. Pinsky DJ, Liao H, Lawson CA, Yan SF, Chen J, Carmeliet P, Loskutoff DJ, Stern DM: Coordinated induction of plasminogen activator inhibitor type-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. J Clin Invest 1998;102:919-928.
15. Stephens RW, Brunner N, Jänicke F, Schmitt M: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat 1998;52:99-111.
16. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brunner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG: The urokinase system of plasminogen activation and prognosis in 2,780 breast cancer patients. Cancer Res 2000;60:636-643.
17. Kaneko T, Konno H, Baba M, Tanaka T, Nakamura S: Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. Cancer Sci 2003;94:43-49.
18. Pedersen H, Brunner N, Francis D, Osterlind K, Ronne E, Hansen HH, Dano K, Grondahl-Hansen J: Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994;54:4671-4675.
19. Hundsdorfer B, Zeilhofer HF, Bock KP, Dettmar P, Schmitt M, Kolk A, Pautke C, Horch HH: Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value. J Craniomaxillofac Surg 2005;33:191-196.
20. Chin D, Boyle GM, Williams RM, Ferguson K, Pandeya N, Pedley J, Campbell CM, Theile DR, Parsons PG, Coman WB: Novel markers for poor prognosis in head and neck cancer. Int J Cancer 2005;113:789-797.
21. Strojan P, Budihna M, Smid L, Vrhovec I, Skrk J: Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck. Anticancer Res 2000;20:3975-3981.
22. Stadler P, Feldmann HJ, Creighton C, Zeilhofer HF, Zimmermann F, Schmitt M, Molls M: Clinical evidence for correlation of insufficient tissue oxygen supply (hypoxia) and tumor-associated proteolysis in squamous cell carcinoma of the head and neck. Int J Biol Markers 2000;15:235-236.
23. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993;24:195-208.
24. Grebenschikov N, Sweep F, Geurts A, Andreasen P, De Witte H, Schousboe S, Heuvel J, Benraad T: ELISA for complexes of urokinase-type and tissue-type plasminogen activators with their type-1 inhibitor (uPAPAI-1 and tPA-PAI-1). Int J Cancer 1999;81:598-606.
25. Papandreou I, Powell A, Lim AL, Denko N: Cellular reaction to hypoxia: sensing and responding to an adverse environment. Mutat Res 2005;569:87-100.
26. Scholzen T, Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-322.
27. Krtolica A, Ludlow JW: Hypoxia arrests ovarian carcinoma cell cycle progression, but invasion is unaffected. Cancer Res 1996;56:1168-1173.
28. Li X, Kimura H, Hirota K, Kasuno K, Torii K, Okada T, Kurooka H, Yokota Y, Yoshida H: Synergistic effect of hypoxia and TNF-α on production of PAI-1 in human proximal renal tubular cells. Kidney Int 2005;68:569-583.
29. 2 sensing. J Biol Chem 2000;275:25130-25138.
30. Moeller BJ, Cao Y, Li CY, Dewhirst MW: Radiation activates HIF-1 to regulate vascular radiosensitivity in tumours: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004;5:429-441.
31. Déry MA, Michaud MD, Richard DE: Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol 2005;37:535-540.
32. Harbeck N, Krüger A, Sinz S, Kates RE, Thomssen C, Schmitt M, Jänicke F: Clinical relevance of the plasminogen activator inhibitor type 1 - a multifaceted proteolytic factor. Onkologie 2001;24:238-244.
33. Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H, Schmitt M: Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Int J Oncol 1998;13:893-906.
34. Kwaan HC, Wang J, Svoboda K, Declerck PJ: Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br J Cancer 2000;82:1702-1708.
35. Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ: Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor type-1. Cancer Res 2000;60:5839-5847.
36. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ: Is plasminogen activator inhibitor type-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996;134:1563-1571.
37. Devy L, Blacher S, Grignet-Debrus C, Bajou K, Masson V, Gerard RD, Gils A. Carmeliet G, Carmeliet P, Declerck PJ, Noel A, Foidart JM: The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 2002;16:147-154.
38. Nordsmark M, Overgaard M, Overgaard J: Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31-39.
39. Stadler P, Becker A, Feldmann HJ, Hänsgen G, Dunst J, Würschmidt F, Molls M: Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 1999;44:749-754.
40. Heaton JH, Dlakic WM, Gelehrter TD: Post-transcriptional regulation of PAI-1 gene expression. Thromb Haemost 2003;89:959-966.
41. Vaupel P, Dunst J, Engert A, Fandrey J, Feyer P, Freund M, Jelkmann W: Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia. Onkologie 2005;28:216-221.
42. Kaanders JH, Pop LA, Marres HA, Bruaset I, van den Hoogen FJ, Merkx MA, van der Kogel AJ: ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;52:769-778.